Topic
Private Credit Research
Within the private credit landscape, researchers emphasize the continued importance of private markets and direct lending as essential tools for diversifying portfolios amidst heightened geopolitical uncertainty and credit stress. While direct lending remains supported, analysts advocate for strict selectivity with a bias toward non-cyclical sectors and infrastructure for inflation-linked income. Credit strategies demonstrated resilience with positive returns in early 2026, though a more defensive posture is emerging through the prioritization of Relative Value and Fixed Income Relative Value sub-strategies. Solid corporate fundamentals and projected S&P 500 EPS growth of 20% support the credit outlook, even as high government deficits pose long-term risks to yields and necessitate a focus on shorter-duration fixed income. Additionally, the massive expansion in AI-related demand, with a projected $1.7 trillion TAM by 2030, and the evolution of biotech into a compounding asset class are creating new long-term investment opportunities for credit providers. Collectively, these insights suggest a research direction focused on resilient, innovation-driven sectors to navigate a goldilocks environment disrupted by macro volatility.
4559 reports available
All reports
Page 150 of 190
Credit Calls
J.P. Morgan · May 18, 2026
Weekly Warm-up Thoughts from the Road
Morgan Stanley · May 18, 2026
Earnings Season Monitor: A Strong Season
Morgan Stanley · May 18, 2026
Australia Macro Mid-Year Outlook
Morgan Stanley · May 18, 2026
Silergy Corp Data Center and Auto Segments Set to Fuel Next Earnings Upcycle
Goldman Sachs · May 18, 2026
China Equity Strategy: Forging New Horizons
Morgan Stanley · May 18, 2026
The Best Thing I Read This Weekend
Goldman Sachs · May 18, 2026
GS Morning update: Thoughts From the Floor and European Views
Goldman Sachs · May 18, 2026
Global Equities Call
Goldman Sachs & Co. LLC · May 18, 2026
Sonova Holdings FY26 Results Supported by Strong Momentum on Hearing Aids Wholesale Business
Goldman Sachs · May 18, 2026
Regeneron Pharmaceuticals Inc. (REGN): Ph3 Anti-LAG-3 Study In First-Line Metastatic Melanoma Fails
Goldman Sachs · May 18, 2026
First Take: FY26 Trading Update - Revenue/EBIT Guide Lowered
Goldman Sachs · May 18, 2026
Bank of Ireland Group: Updating Estimates Post Q1 2026 IMS
Goldman Sachs International · May 18, 2026
European Contextual Diary
UBS · May 18, 2026
New Zealand Morning Focus
ANZ · May 18, 2026
Strategic Pivot Towards AIDC
Goldman Sachs · May 18, 2026
GS European Express
Goldman Sachs · May 18, 2026
TMT Specialist Sales Update
Goldman Sachs · May 18, 2026
Market Colour and Corporate Updates
Goldman Sachs · May 18, 2026
Today's Morning Meeting
J.P. Morgan · May 18, 2026
What US and EU PPI Tell Us About Multi Industry
Goldman Sachs · May 18, 2026
UK and European Research at a Glance
RBC Capital Markets · May 18, 2026
Krishna Institute of Medical Sciences 4Q25 Results Update
Goldman Sachs · May 18, 2026
European Retailing: Profit is Sanity but Cash is Reality
RBC Capital Markets · May 18, 2026